Eric Easom, CEO of AN2 Therapeutics
Anacor veterans raise $80M in bid to tackle rare lung disease with boron-based inhibitors
After starting up with a $12 million Series A in 2019, California outfit AN2 Therapeutics issued its first press release in over 2 years …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
